zacks.com / Page 3

SRE matches Q1 earnings estimates as strong infrastructure and Texas utility results help offset lower revenues and rising debt.

MCK heads into Q4 earnings with strength in oncology, GLP-1 demand, and biopharma services, but softer medical-surgical trends may weigh.

Trimble beat Q1'26 earnings and revenue estimates as ARR hit $2.43B, margins expand, and raises 2026 guidance.

PPL to report first-quarter earnings on May 8, data-center demand and grid upgrades may lift results, but premium valuation adds caution.

DigitalOcean beats Q1 2026 estimates as revenues rise 22% and AI ARR surges 221%, lifts 2026 guidance.

JBT (JBTM) possesses solid growth attributes, which could help it handily outperform the market.

LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Napco (NSSC) possesses solid growth attributes, which could help it handily outperform the market.

ZTS misses on Q1 earnings and cuts its 2026 revenue outlook as weaker U.S. companion animal sales pressured results, sending shares down in pre-market trading.